RIVAROXABAN OF THE BAYER COMPANY SIGNIFICANTLY (BY 24%) REDUCES THE RISK OF STROKE, CARDIOVASCULAR DEATH AND MYOCARDIAL INFARCTION IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE OR PERIPHERAL ARTERIAL DISEASE
Press release of JSC "BAYER"
Saved in:
| Main Author: | статья Редакционная |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2017-11-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Online Access: | https://www.rpcardio.online/jour/article/view/1543 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bayer registered a new indication for rivaroxaban for use in patients with coronary heart disease or peripheral artery disease in the European Union and USA
by: Bayer Company Press Release
Published: (2018-11-01) -
The Results of Rivaroxaban Studies COMMANDER HF and MARINER Were Published. Bayer Company Press Release .
by: artilce Editorial
Published: (2019-01-01) -
NEW DATA OF EXTENSIVE RESEARCH PROGRAM AND THE RESULTS OF STUDIES IN REAL CLINICAL PRACTICE FROM DIFFERENT COUNTRIES REAFFIRMED THE HIGH EFFICACY AND A FAVORABLE SAFETY PROFILE OF RIVAROXABAN (XARELTO®) FROM THE BAYER COMPANY PRESS RELEASE OF THE BAYER COMPANY
by: article editorial
Published: (2017-01-01) -
EDITORIAL COMMENTS ON THE ARTICLE OF D.S. KRIVONOSOV ET AL “OPTIMIZATION OF THE TREATMENT OF ELDERLY PATIENTS WITH MYOCARDIAL INFARCTION BY REVASCULARIZATION IN COMBINATION WITH INOTROPIC STIMULATION AND MYOCARDIAL UNLOADING”
by: статья Редакционная
Published: (2016-01-01) -
Clopidogrel combined with rivaroxaban in peripheral artery disease after revascularization
by: Min Lu, et al.
Published: (2025-01-01)